Patents by Inventor Kulvi Kaur

Kulvi Kaur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11542556
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: January 3, 2023
    Assignee: Millennium Health, LLC
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur
  • Publication number: 20210123102
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Application
    Filed: June 9, 2020
    Publication date: April 29, 2021
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur
  • Patent number: 10683548
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: June 16, 2020
    Assignee: Millennium Health, LLC
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur
  • Publication number: 20180216190
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 2, 2018
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur
  • Patent number: 9932638
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: April 3, 2018
    Assignee: Millennium Health, LLC
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur
  • Publication number: 20160376656
    Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Inventors: Hua Fang, Xiequn Xu, Tanya Moreno, Matthew Dedek, Kulvi Kaur